Cantor Fitzgerald Weighs in on ALX Oncology FY2025 Earnings

ALX Oncology Holdings Inc. (NASDAQ:ALXO) – Analysts at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for ALX Oncology in a report issued on Monday, November 10th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings of ($1.82) per share for the year, down from their previous estimate of ($1.71). The consensus estimate for ALX Oncology’s current full-year earnings is ($2.76) per share. Cantor Fitzgerald also issued estimates for ALX Oncology’s FY2026 earnings at ($0.85) EPS.

ALX Oncology (NASDAQ:ALXO) last released its quarterly earnings data on Friday, November 7th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.04).

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of ALX Oncology in a research note on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $3.30.

ALX Oncology Stock Performance

Shares of ALXO opened at $1.31 on Wednesday. ALX Oncology has a 12-month low of $0.40 and a 12-month high of $2.27. The stock has a market cap of $71.03 million, a P/E ratio of -0.65 and a beta of 1.23. The company has a current ratio of 2.40, a quick ratio of 4.52 and a debt-to-equity ratio of 0.13. The company has a 50-day moving average of $1.50 and a two-hundred day moving average of $0.91.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Almitas Capital LLC boosted its stake in ALX Oncology by 10.6% in the 1st quarter. Almitas Capital LLC now owns 1,353,141 shares of the company’s stock worth $843,000 after buying an additional 130,196 shares during the last quarter. Nuveen LLC purchased a new position in shares of ALX Oncology during the 1st quarter worth about $103,000. Acadian Asset Management LLC grew its holdings in ALX Oncology by 16.8% in the first quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company’s stock valued at $806,000 after purchasing an additional 186,883 shares during the period. Jane Street Group LLC acquired a new position in ALX Oncology during the second quarter worth approximately $84,000. Finally, AQR Capital Management LLC grew its stake in shares of ALX Oncology by 183.6% during the 1st quarter. AQR Capital Management LLC now owns 119,050 shares of the company’s stock valued at $74,000 after buying an additional 77,065 shares during the period. Hedge funds and other institutional investors own 97.97% of the company’s stock.

Insider Activity at ALX Oncology

In other news, CEO Jason Lettmann acquired 71,163 shares of the business’s stock in a transaction dated Wednesday, September 17th. The stock was acquired at an average price of $1.08 per share, with a total value of $76,856.04. Following the completion of the transaction, the chief executive officer directly owned 305,121 shares in the company, valued at approximately $329,530.68. This represents a 30.42% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 21.00% of the stock is currently owned by company insiders.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.